Jonathan J Duplisea1, Sharada Mokkapati1, Devin Plote2, Kimberly S Schluns3, David J McConkey4, Seppo Yla-Herttuala5, Nigel R Parker6, Colin P Dinney7. 1. Department of Urology, The University of Texas MD Anderson Cancer Center, 1220 Holcombe Blvd Floor 7, Houston, TX, 77030, USA. 2. Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 3. Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 4. James Buchanan Brady Urological Institute, Johns Hopkins Greenberg Bladder Cancer Institute, Johns Hopkins University, School of Medicine, Baltimore, MD, USA. 5. A.I.Virtanen Institute, University of Eastern Finland and Gene Therapy Unit, Kuopio University Hospital, Kuopio, Finland. 6. Hamesman Ltd., London, UK. 7. Department of Urology, The University of Texas MD Anderson Cancer Center, 1220 Holcombe Blvd Floor 7, Houston, TX, 77030, USA. cdinney@mdanderson.org.
Abstract
BACKGROUND AND PURPOSE: BCG unresponsive bladder cancer is an inherently resistant disease state for which the preferred treatment is radical cystectomy. To date, no effective intravesical therapies exist for patients who possess these resistant tumors. For this reason, many research groups are actively investigating/testing novel therapeutic agents to aid in bladder preservation for this patient population. This review article describes our 15-year experience developing and testing IFN-based gene therapy. METHODS: A comprehensive review was performed of all studies pertaining to IFN-based gene therapy for non-muscle invasive bladder cancer from 2003 to 2018. RESULTS AND CONCLUSIONS: Over the past two decades, gene therapy has evolved into a powerful tool in our fight against cancer. After overcoming the initial barriers associated with gene delivery to the bladder, we have made significant strides forward in developing this novel therapeutic strategy for the treatment of this inherently resistant disease state. Our results to date are very encouraging; however, much work lies ahead to better understand and optimize this novel approach for treating non-muscle invasive bladder.
BACKGROUND AND PURPOSE:BCG unresponsive bladder cancer is an inherently resistant disease state for which the preferred treatment is radical cystectomy. To date, no effective intravesical therapies exist for patients who possess these resistant tumors. For this reason, many research groups are actively investigating/testing novel therapeutic agents to aid in bladder preservation for this patient population. This review article describes our 15-year experience developing and testing IFN-based gene therapy. METHODS: A comprehensive review was performed of all studies pertaining to IFN-based gene therapy for non-muscle invasive bladder cancer from 2003 to 2018. RESULTS AND CONCLUSIONS: Over the past two decades, gene therapy has evolved into a powerful tool in our fight against cancer. After overcoming the initial barriers associated with gene delivery to the bladder, we have made significant strides forward in developing this novel therapeutic strategy for the treatment of this inherently resistant disease state. Our results to date are very encouraging; however, much work lies ahead to better understand and optimize this novel approach for treating non-muscle invasive bladder.
Authors: C M Iqbal Ahmed; D E Johnson; G W Demers; H Engler; J A Howe; K N Wills; S F Wen; J Shinoda; J Beltran; M Nodelman; T Machemer; D C Maneval; T L Nagabhushan; B J Sugarman Journal: Cancer Gene Ther Date: 2001-10 Impact factor: 5.987
Authors: Jonathan I Izawa; Paul Sweeney; Paul Perrotte; Daniel Kedar; Zhongyun Dong; Joel W Slaton; Takashi Karashima; Keji Inoue; William F Benedict; Colin P N Dinney Journal: Clin Cancer Res Date: 2002-04 Impact factor: 12.531
Authors: Zofia von Marschall; Arne Scholz; Thorsten Cramer; Georgia Schäfer; Michael Schirner; Kjell Oberg; Bertram Wiedenmann; Michael Höcker; Stefan Rosewicz Journal: J Natl Cancer Inst Date: 2003-03-19 Impact factor: 13.506
Authors: F M Torti; L D Shortliffe; R D Williams; W C Pitts; R L Kempson; J C Ross; J Palmer; F Meyers; M Ferrari; J Hannigan Journal: J Clin Oncol Date: 1988-03 Impact factor: 44.544
Authors: Seth P Lerner; Colin Dinney; Ashish Kamat; Trinity J Bivalacqua; Matthew Nielsen; Michael O'Donnell; Mark P Schoenberg; Gary Steinberg Journal: Bladder Cancer Date: 2015-03-30
Authors: Anirban P Mitra; Vikram M Narayan; Sharada Mokkapati; Tanner Miest; Stephen A Boorjian; Mehrdad Alemozaffar; Badrinath R Konety; Neal D Shore; Leonard G Gomella; Ashish M Kamat; Trinity J Bivalacqua; Jeffrey S Montgomery; Seth P Lerner; J Erik Busby; Michael Poch; Paul L Crispen; Gary D Steinberg; Anne K Schuckman; Tracy M Downs; Robert S Svatek; Joseph Mashni; Brian R Lane; Thomas J Guzzo; Gennady Bratslavsky; Lawrence I Karsh; Michael E Woods; Gordon A Brown; Daniel Canter; Adam Luchey; Yair Lotan; Tracey Krupski; Brant A Inman; Michael B Williams; Michael S Cookson; Kirk A Keegan; Gerald L Andriole; Alexander I Sankin; Alan Boyd; Michael A O'Donnell; Richard Philipson; Seppo Ylä-Herttuala; David Sawutz; Nigel R Parker; David J McConkey; Colin P N Dinney Journal: Eur Urol Date: 2021-12-18 Impact factor: 24.267
Authors: Alessandro Audisio; Consuelo Buttigliero; Marco Donatello Delcuratolo; Elena Parlagreco; Marco Audisio; Antonio Ungaro; Rosario Francesco Di Stefano; Lavinia Di Prima; Fabio Turco; Marcello Tucci Journal: Cells Date: 2022-01-21 Impact factor: 6.600